Gender-neutral language is increasingly being adopted across different industries, including in certain health care and pharmaceutical communications, to be more inclusive towards a wider range of people. By using terms such as “individuals with a prostate” or “patients with breast cancer,” the communications in question are aiming to consider the experiences of transgender individuals, whose gender identity is different to their physical sex.
How Can Pharma Seek To Discuss Gender Diversity?
Communications Ought To Be Both Accessible And Inclusive
As gender-neutral language becomes more widely used throughout the business community, the pharmaceutical industry must confront how it approaches the matter of gendered language in healthcare communications.
More from Diversity & Inclusion
• By
The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.
• By
Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.
• By
Looking at a recent McKinsey report alongside our Evaluate data, the below infographic provides insight into the investment scene of pharma and raises questions as to how the industry is seemingly yet to seize the opportunity in women's health.
• By
Despite significant investments in weight loss treatments, pharmaceutical companies face criticism for neglecting to study their drugs in obese patients, possibly leading to incomplete labeling and patient risks, prompting calls for the FDA to enforce more inclusive clinical trials and updated drug information.
More from ESG
• By
As efforts to improve diversity in clinical trials gain momentum globally, regulators in the UK, the EU, Canada, Australia and Japan were asked about their efforts to support representative enrolment.
• By
Royal Philips is at the forefront of the driving environmental sustainability along the Scope 1-2-3 chain. The company hosted a round table in Amsterdam to hear experiences from providers.
• By
The US FDA’s Office of Women’s Health provides a research roadmap to address health concerns specific to women. The FDA recently updated the roadmap, outlining areas in which further research is needed.